MHRP’s first DELIVER study, a Phase 1 clinical trial called DELIVER-01/RV630, launched in Thailand in 2025 to test a combination of experimental antibodies and vaccines to assess their safety and potential to control HIV without antiretroviral therapy (ART) in people living with the virus.
This study is enrolling participants from the RV254 cohort in Thailand, which is made up of individuals diagnosed during the early acute stages of HIV infection who are on ART and have maintained undetectable viral loads.
Researchers are evaluating two long-acting antibodies, VRC07-523LS and PGDM1400LS, used alongside a series of HIV vaccine candidates including ChAdOx1 and MVA vaccine platforms and an adjuvanted gp120 protein vaccine. The study design includes a closely monitored analytical treatment interruption, when participants will stop ART to see whether the combination of study products continues to suppress viral load.
